Off-target binding happens when a drug interacts with unintended proteins, which can lead to adverse effects, reduced efficacy, and regulatory hurdles. Identifying these interactions early in the drug development process enables researchers to select low-risk candidates, increasing the likelihood of success in clinical trials.
Download this ebook to learn more about:
- How off-target interactions contribute to toxicity and clinical trial or regulatory failure
- Methods for assessing drug specificity and minimizing unintended binding
- Strategies for incorporating off-target screening into preclinical research
